BVX — Bivictrix Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- £9.49m
- £8.00m
2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS |
Standards: | — | IFRS | IFRS |
Status: | Final | Final | Final |
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 0.49 | 1.89 | 2.98 |
Operating Profit | -0.49 | -1.89 | -2.98 |
Total Net Non Operating Interest Income / Expense | |||
Net Income Before Taxes | -0.509 | -2.53 | -2.97 |
Provision for Income Taxes | |||
Net Income After Taxes | -0.425 | -2.34 | -2.5 |
Net Income Before Extraordinary Items | |||
Net Income | -0.425 | -2.34 | -2.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -0.425 | -2.34 | -2.5 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.006 | -0.054 | -0.038 |
Dividends per Share |